SequelSEC

Yubo International Biotech Ltd YBGJ

Electromedical & Electrotherapeutic Apparatus · CIK 0000895464 · Fiscal year ends 1231

Revenue
$12.35K
Fiscal year ended 2025-12-31
Operating income
-$1.19M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$1Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.00Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.0×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Electromedical & Electrotherapeutic Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Operating margin-9614.6%4th
Net margin-8736.7%4th
Current ratio0.24x7th
Revenue YoY growth256.0%93th
Gross margin66.1%70th

Yubo International Biotech Ltd (YBGJ) reported revenue of $12.35K and net income of -$1.08M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Yubo International Biotech Ltd’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

Yubo International Biotech Ltd income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-02-292019-02-282018-02-282017-02-282016-02-29
Revenue$12.35K$3.47K$604.68K$104.28K$1.24M$0$0$0$0$0
Cost of revenue$4.19K$822$185.49K$51.63K$423.73KUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profit$8.16K$2.65K$419.18K$52.65K$820.65KUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$1.19M-$1.77M-$1.19M-$1.21M-$1.54M-$29.00K-$48.00K-$58.00K-$149.00K-$63.00K
Net income-$1.08M-$1.78M-$1.20M-$1.20M-$1.54M-$134.00K-$148.00K-$144.00K-$224.00K-$130.00K
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 139.64Mshares 119.82Mshares 11.98MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$1.19M-$1.98M-$1.20M-$1.20M-$1.54MUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPS$-0.01$-0.02$-0.10UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable$29.00K$48.00K$58.00K$149.00K$63.00K
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Yubo International Biotech Ltd balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-02-292019-02-282018-02-282017-02-282016-02-29
Cash & equivalents$8.06K$7.02K$6.36K$18.22K$27.52K$1.00K$4.00K$2.00K$1.00K$11.00K
Total assets$847.09K$1.53M$1.67M$2.35M$4.59M$1.00K$4.00KUnavailableUnavailable$14.00K
Current assets$667.51K$682.75K$725.24K$750.01K$1.06M$1.00K$4.00K$5.00K$4.00K$14.00K
Total liabilities$2.79M$4.83M$3.51M$2.91M$4.72M$1.80MUnavailableUnavailableUnavailable$1.27M
Current liabilities$2.79M$4.72M$3.40M$2.52M$2.79M$1.80M$1.67M$1.52M$1.38M$1.27M
Total equity incl. NCI-$1.94M-$3.30M-$1.84M-$565.37K-$131.20K-$1.80M-$1.66M-$1.52M-$1.37M-$1.26M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$24.03K$36.95K$214.58K$322.17K$164.30KUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$138.04K$164.98K$79.65K$51.93K$161.96KUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailable$353.00K$342.00K$332.00K$325.00K$415.00K

Cash flow

Yubo International Biotech Ltd cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-02-292019-02-282018-02-282017-02-282016-02-29
Operating cash flow-$842.80K-$1.34M-$738.97K-$600.95K-$1.02M-$22.00K-$32.00K-$55.00K-$55.00K-$56.00K
Capital expendituresUnavailableUnavailableUnavailable$0$564.72KUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$0$118.43K$0-$39.77K-$564.72K$0$0$0$0Unavailable
Financing cash flow$849.54K$1.41M$745.66K$669.19K$127.16K$19.00K$34.00K$56.00K$45.00K$55.00K
Net change in cash$1.05K$656-$11.86K-$9.30K-$1.36M-$3.00K$2.00K$1.00K-$10.00K-$1.00K
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$167.58K$169.88K$178.31K$18.10K$13.22KUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Yubo International Biotech Ltd derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-02-292019-02-282018-02-282017-02-282016-02-29
Free cash flowUnavailableUnavailableUnavailableUnavailable-$1.59MUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin66.1%76.3%69.3%50.5%65.9%UnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-9614.6%-51006.3%-197.6%-1155.7%-124.0%UnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable-127.4%UnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.24x0.14x0.21x0.30x0.38x0.00x0.00x0.00x0.00x0.01x
Revenue YoY growth256.0%-99.4%479.8%-91.6%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net margin-8736.7%-51171.4%-197.6%-1155.5%-124.0%UnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable45.4%UnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open YBGJ in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.